Navigation Links
Array BioPharma Announces Exercise And Closing Of Underwriters' Over-Allotment Option
Date:12/5/2012

BOULDER, Colo., Dec. 5, 2012 /PRNewswire/ -- Array BioPharma Inc. (NasdaqGM: ARRY) announced today the sale of 2,700,000 shares of its common stock pursuant to the exercise of the over-allotment option granted to the underwriters in connection with Array's previously announced underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $3.65 per share. The total net proceeds to Array, including from the exercise of the over-allotment option, were $70.9 million, after deducting underwriting discounts and estimated expenses. Jefferies & Company, Inc. and J.P. Morgan Securities LLC acted as joint book-running managers for the offering, with Piper Jaffray & Co., Stifel Nicolaus Weisel and William Blair acting as co-managers.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO )

The shares were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. 

A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained from either: Jefferies & Company, Inc., Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling (866) 803-9204.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. 

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the expected use of proceeds of the offering and other statements that are other than statements of historical facts. These statements involve significant risks and uncertainties. Because these statements reflect our current expectations concerning future events, our actual events could differ materially from those anticipated in these forward-looking statements as a result of many factors. Additional information concerning factors that may cause actual events to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of Array's most recent Annual Report on Form 10-K, in our other periodic reports and filings with the Securities and Exchange Commission and in the prospectus supplement related to the offering. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Array on the date hereof, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

CONTACT:

Tricia Haugeto


(303) 386-1193


thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. John A. Orwin Joins Array BioPharma Board Of Directors
2. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
3. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
4. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
7. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
8. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
9. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
Breaking Biology News(10 mins):